Q-omics provides the consensus-scored NDUFB3 profile across patient tissues and cancer cell-line models. NDUFB3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFB3 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, NDUFB3 protein abundance shows 19,654 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where NDUFB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB3 survival associations across molecular data types. NDUFB3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB3 RNA expression–survival associations across cancer types. High NDUFB3 expression shows unfavorable associations in UVM, KICH, ACC, LUAD, ESCA and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFB3 RNA expression.
This table summarizes NDUFB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB3 shows lower tumor expression in KIRC, KICH, THCA and COAD and higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher NDUFB3 RNA expression in tumor versus normal tissue (log2 FC = +0.945, t-test p < 0.001).
This table shows molecular features associated with NDUFB3 in patient tissues and cancer cell lines. In patient samples, NDUFB3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
